SUPPLEMENT

Q2 2021 — Financial disclosures

Q2 2021PDF · 10 pages1000 KB
Merck & Co., Inc.
Financial Highlights Package
Second Quarter 2021
Table of Contents
Table 1: GAAP P&L....................................................................................1
Table 1a: GAAP P&L – Current Year and Prior Year by Quarter.................2
Table 2a: GAAP to Non-GAAP Reconciliation 2Q21 and June YTD 21.......3
Table 2b: GAAP to Non-GAAP Reconciliation 2Q20 and June YTD 20.......4
Table 3: Sales - Current Year and Prior Year by Quarter...........................5
Table 3a: Sales – U.S. / Ex- U.S. 2Q21........................................................6
Table 3b: Sales – U.S. / Ex- U.S. June YTD 21............................................7
Table 3c: Sales – Pharmaceutical Geographic Split....................................8
Table 4: Other (Income) Expense .............................................................9

-- 1 of 10 --

Sales 	11,402	$ 	9,353	$ 	22% 	22,029	$ 	19,641	$ 	12%
Costs, Expenses and Other
Cost of sales 	3,104 	2,747 	13% 	6,303 	5,576 	13%
Selling, general and administrative 	2,281 	2,085 	9% 	4,468 	4,276 	4%
Research and development 	4,321 	2,085 	* 	6,732 	4,260 	58%
Restructuring costs (1) 82 	82 	0% 	380 	152 	*
Other (income) expense, net 	(103) 	(387) 	-73% 	(558) 	(325) 	72%
Income from Continuing Operations Before Taxes 	1,717 	2,741 	-37% 	4,704 	5,702 	-18%
Income Tax Provision 	503 	396 	741 	891
Net Income from Continuing Operations 	1,214 	2,345 	-48% 	3,963 	4,811 	-18%
Less: Net Income (Loss) Attributable to Noncontrolling Interests 	1 	4 	5 	(1)
Net Income from Continuing Operations Attributable to Merck & Co.,
Inc. 1,213	$ 	2,341	$ 	-48% 	3,958	$ 	4,812	$ 	-18%
Income from Discontinued Operations, Net of Taxes and Amounts
Attributable to Noncontrolling Interests 332	$ 	661	$ 	-50% 	766	$ 	1,409	$ 	-46%
Net Income Attributable to Merck & Co., Inc. 	1,545	$ 	3,002	$ 	-49% 	4,724	$ 	6,221	$ 	-24%
Basic Earnings per Common Share Attributable to Merck & Co., Inc.
Common Shareholders:
Income from Continuing Operations 	0.48	$ 	0.93	$ 	-48% 	1.56	$ 	1.90	$ 	-18%
Income from Discontinued Operations 	0.13	$ 	0.26	$ 	-50% 	0.30	$ 	0.56	$ 	-46%
Net Income 	0.61	$ 	1.19	$ 	-49% 	1.87	$ 	2.46	$ 	-24%
Earnings per Common Share Assuming Dilution Attributable to Merck
& Co., Inc. Common Shareholders:
Income from Continuing Operations 	0.48	$ 	0.92	$ 	-48% 	1.56	$ 	1.89	$ 	-17%
Income from Discontinued Operations 	0.13	$ 	0.26	$ 	-50% 	0.30	$ 	0.55	$ 	-45%
Net Income 	0.61	$ 	1.18	$ 	-48% 	1.86	$ 	2.45	$ 	-24%
Average Shares Outstanding 	2,533 	2,527 	2,532 	2,531
Average Shares Outstanding Assuming Dilution 	2,540 	2,536 	2,540 	2,542
Tax Rate from Continuing Operations (2) 29.3% 	14.4% 	15.8% 	15.6%
* 100% or greater
(2) The effective income tax rates for the second quarter and first six months of 2021 reflect the unfavorable impact of a charge for the acquisition of Pandion Therapeutics, Inc. for
which no tax benefit was recognized. Additionally, the effective income tax rate for the first six months of 2021 reflects a net tax benefit of $207 million related to the settlement of
certain federal income tax matters.
MERCK & CO., INC.
CONSOLIDATED STATEMENT OF INCOME - GAAP
(AMOUNTS IN MILLIONS, EXCEPT PER SHARE FIGURES)
(UNAUDITED)
Table 1
GAAP
% Change
GAAP
% Change
2Q21
On June 2, 2021, Merck completed the spinoff of products from its women’s health, biosimilars and established brands businesses into a new,
independent, publicly traded company named Organon & Co. (Organon) through a distribution of Organon’s publicly traded stock to company
shareholders. The historical results of the women’s health, biosimilars and established brands businesses that were contributed to Organon in the spin-off
are excluded from sales and expenses below and reflected as discontinued operations in the company’s Consolidated Statements of Income provided
below.
2Q20 June YTD
2021
June YTD
2020
(1) Represents separation and other related costs associated with restructuring activities under the company's formal restructuring programs.
1

-- 2 of 10 --

Sales 	10,627	$ 	11,402	$ 	22,029	$ 	10,288	$ 	9,353	$ 	19,641	$ 	10,929	$ 	10,948	$ 	41,518	$ 	22% 	12%
Costs, Expenses and Other
Cost of sales 	3,199 	3,104 	6,303 	2,829 	2,747 	5,576 	3,013 	5,029 	13,618 	13% 	13%
Selling, general and administrative 	2,187 	2,281 	4,468 	2,191 	2,085 	4,276 	2,060 	2,619 	8,955 	9% 	4%
Research and development 	2,412 	4,321 	6,732 	2,175 	2,085 	4,260 	3,349 	5,788 	13,397 	* 	58%
Restructuring costs 	297 	82 	380 	70 	82 	152 	113 	310 	575 	0% 	*
Other (income) expense, net 	(455) 	(103) 	(558) 	62 	(387) 	(325) 	(312) 	(253) 	(890) 	-73% 	72%
Income (Loss) from Continuing Operations Before Taxes 	2,987 	1,717 	4,704 	2,961 	2,741 	5,702 	2,706 	(2,545) 	5,863 	-37% 	-18%
Income Tax Provision 	238 	503 	741 	495 	396 	891 	380 	69 	1,340
Net Income (Loss) from Continuing Operations 	2,749 	1,214 	3,963 	2,466 	2,345 	4,811 	2,326 	(2,614) 	4,523 	-48% 	-18%
Less: Net Income (Loss) Attributable to Noncontrolling Interests 	4 	1 	5 	(5) 	4 	(1) 	2 	3 	4
Net Income (Loss) from Continuing Operations Attributable to
Merck & Co., Inc.
2,745 	1,213 	3,958 	2,471 	2,341 	4,812 	2,324 	(2,617) 	4,519 	-48% 	-18%
Income from Discontinued Operations, Net of Taxes and
Amounts Attributable to Noncontrolling Interests
434 	332 	766 	748 	661 	1,409 	617 	523 	2,548 	-50% 	-46%
Net Income (Loss) Attributable to Merck & Co., Inc. 	3,179	$ 	1,545	$ 	4,724	$ 	3,219	$ 	3,002	$ 	6,221	$ 	2,941	$ 	(2,094)	$ 	7,067	$ 	-49% 	-24%
Basic Earnings (Loss) per Common Share Attributable to Merck
& Co., Inc. Common Shareholders:
Income (Loss) from Continuing Operations 	1.08	$ 	0.48	$ 	1.56	$ 	0.98	$ 	0.93	$ 	1.90	$ 	0.92	$ 	(1.03)	$ 	1.79	$ 	-48% 	-18%
Income from Discontinued Operations 	0.17 	0.13 	0.30 	0.30 	0.26 	0.56 	0.24 	0.21 	1.01 	-50% 	-46%
Net Income (Loss) 	1.26	$ 	0.61	$ 	1.87	$ 	1.27	$ 	1.19	$ 	2.46	$ 	1.16	$ 	(0.83)	$ 	2.79	$ 	-49% 	-24%
Earnings (Loss) per Common Share Assuming Dilution
Attributable to Merck & Co., Inc. Common Shareholders:
Income (Loss) from Continuing Operations 	1.08	$ 	0.48	$ 	1.56	$ 	0.97	$ 	0.92	$ 	1.89	$ 	0.92	$ 	(1.03)	$ 	1.78	$ 	-48% 	-17%
Income from Discontinued Operations 	0.17 	0.13 	0.30 	0.29 	0.26 	0.55 	0.24 	0.21 	1.00 	-50% 	-45%
Net Income (Loss) 	1.25	$ 	0.61	$ 	1.86	$ 	1.26	$ 	1.18	$ 	2.45	$ 	1.16	$ 	(0.83)	$ 	2.78	$ 	-48% 	-24%
Average Shares Outstanding 	2,531 	2,533 	2,532 	2,533 	2,527 	2,531 	2,529 	2,530 	2,530
Average Shares Outstanding Assuming Dilution (1) 	2,541 	2,540 	2,540 	2,547 	2,536 	2,542 	2,538 	2,530 	2,541
Tax Rate from Continuing Operations 	8.0% 	29.3% 	15.8% 	16.7% 	14.4% 	15.6% 	14.0% 	-2.7% 	22.9%
* 100% or greater
Sum of quarterly amounts may not equal year-to-date amounts due to rounding.
Table 1a
MERCK & CO., INC.
CONSOLIDATED STATEMENT OF INCOME - GAAP
(AMOUNTS IN MILLIONS, EXCEPT PER SHARE FIGURES)
(UNAUDITED)
(1) Because the company recorded a net loss in the fourth quarter of 2020, no potential dilutive common shares were used in the computation of loss per common share assuming dilution as the
effect would have been anti-dilutive. Income from discontinued operations was also computed using average common shares outstanding.
2021
2Q 	June YTD	1Q 	1Q 	2Q 	3Q 	4Q 	Full Year
2020 % Change
2Q June
YTD
June YTD
2

-- 3 of 10 --

Second Quarter
Cost of sales 	3,104	$ 	345 	38 	37 (3) 420 	2,684	$
Selling, general and administrative 	2,281 	25 	2 	27 	2,254
Research and development 	4,321 	16 	6 	1,765 (4) 1,787 	2,534
Restructuring costs 	82 	82 	82 	-
Other (income) expense, net 	(103) 	117 	(258) 	(141) 	38
Income From Continuing Operations Before Taxes 	1,717 	(503) 	(128) 	258 	(1,802) 	(2,175) 	3,892
Income Tax Provision (Benefit) 	503 	(98) (5) (15) (5) 57 (5) (11) (5) (67) 	570
Net Income from Continuing Operations 	1,214 	(405) 	(113) 	201 	(1,791) 	(2,108) 	3,322
Net Income from Continuing Operations Attributable
to Merck & Co., Inc. 1,213 	(405) 	(113) 	201 	(1,791) 	(2,108) 	3,321
Earnings per Common Share Assuming Dilution from
Continuing Operations 0.48	$ 	(0.16) 	(0.04) 	0.08 	(0.71) 	(0.83) 	1.31	$
Tax Rate 	29.3% 	14.6%
June YTD
Cost of sales 	6,303	$ 	842 	65 	225 (3) 1,132 	5,171	$
Selling, general and administrative 	4,468 	35 	4 	39 	4,429
Research and development 	6,732 	34 	13 	1,765 (4) 1,812 	4,920
Restructuring costs 	380 	380 	380 	-
Other (income) expense, net 	(558) 	89 	(819) 	(730) 	172
Income From Continuing Operations Before Taxes 	4,704 	(1,000) 	(462) 	819 	(1,990) 	(2,633) 	7,337
Income Tax Provision (Benefit) 	741 	(187) (5) (56) (5) 180 (5) (260) (5) (323) 	1,064
Net Income from Continuing Operations 	3,963 	(813) 	(406) 	639 	(1,730) 	(2,310) 	6,273
Net Income from Continuing Operations Attributable
to Merck & Co., Inc. 3,958 	(813) 	(406) 	639 	(1,730) 	(2,310) 	6,268
Earnings per Common Share Assuming Dilution from
Continuing Operations 1.56	$ 	(0.32) 	(0.16) 	0.25 	(0.68) 	(0.91) 	2.47	$
Tax Rate 	15.8% 	14.5%
Only the line items that are affected by non-GAAP adjustments are shown.
Adjustment Subtotal 	Non-GAAP
MERCK & CO., INC.
SECOND QUARTER AND SIX MONTHS ENDED JUNE 30, 2021 GAAP TO NON-GAAP RECONCILIATION - CONTINUING OPERATIONS
(AMOUNTS IN MILLIONS, EXCEPT PER SHARE FIGURES)
(UNAUDITED)
The table below reflects a reconciliation of GAAP to non-GAAP financial information on a continuing operations basis. As Organon results are reflected within discontinued operations, they are
excluded from the financial information provided below.
GAAP Acquisition and Divestiture-
Related Costs (1) 	Restructuring Costs (2)
(Income) Loss from
Investments in Equity
Securities
Certain Other Items
Table 2a
Merck is providing certain non-GAAP information that excludes certain items because of the nature of these items and the impact they have on the analysis of underlying business performance and trends. Management
believes that providing this information enhances investors’ understanding of the company’s results as it permits investors to understand how management assesses performance. Management uses these measures
internally for planning and forecasting purposes and to measure the performance of the company along with other metrics. In addition, senior management’s annual compensation is derived in part using non-GAAP pretax
income. This information should be considered in addition to, but not as a substitute for or superior to, information prepared in accordance with GAAP.
(1) Amounts included in cost of sales primarily reflect expenses for the amortization of intangible assets. Amounts included in selling, general and administrative expenses reflect acquisition and divestiture-related costs.
Amounts included in research and development expenses primarily reflect expenses for the amortization of intangible assets. Amounts included in other (income) expense, net, for the second quarter and six months period
primarily reflect an increase in the estimated fair value measurement of liabilities for contingent consideration related to the termination of the Sanofi-Pasteur MSD joint venture and a loss on a forward exchange contract
entered into in conjunction with the Organon spinoff. Amount included in other (income) expense, net, for the six month period is partially offset by royalty income related to the termination of the Sanofi-Pasteur MSD joint
venture.
(2) Amounts primarily include employee separation costs and accelerated depreciation associated with facilities to be closed or divested related to activities under the company's formal restructuring programs.
(3) Represents charges for the discontinuation of COVID-19 development programs.
(5) Represent the estimated tax impacts on the reconciling items based on applying the statutory rate of the originating territory of the non-GAAP adjustments. Certain other items for the six month period also includes a
$207 million net tax benefit related to the settlement of certain federal income tax matters.
(4) Includes a $1.7 billion charge for the acquisition of Pandion Therapeutics, Inc.
3

-- 4 of 10 --

Second Quarter
Cost of sales 	2,747	$ 	580 	25 	605 	2,142	$
Selling, general and administrative 	2,085 	44 	11 	55 	2,030
Research and development 	2,085 	(63) 	31 	(32) 	2,117
Restructuring costs 	82 	82 	82 	-
Other (income) expense, net 	(387) 	63 	(511) 	(16) 	(464) 	77
Income From Continuing Operations Before Taxes 	2,741 	(624) 	(149) 	511 	16 	(246) 	2,987
Income Tax Provision (Benefit) 	396 	(91) (3) (27) (3) 112 (3) 5 (3) (1) 	397
Net Income from Continuing Operations 	2,345 	(533) 	(122) 	399 	11 	(245) 	2,590
Net Income from Continuing Operations Attributable
to Merck & Co., Inc. 2,341 	(533) 	(122) 	399 	11 	(245) 	2,586
Earnings per Common Share Assuming Dilution from
Continuing Operations 0.92	$ 	(0.21) 	(0.05) 	0.16 	- 	(0.10) 	1.02	$
Tax Rate 	14.4% 	13.3%
June YTD
Cost of sales 	5,576	$ 	968 	93 	1,061 	4,516	$
Selling, general and administrative 	4,276 	157 	22 	179 	4,097
Research and development 	4,260 	(23) 	48 	25 	4,235
Restructuring costs 	152 	152 	152 	-
Other (income) expense, net 	(325) 	52 	(598) 	(16) 	(562) 	237
Income From Continuing Operations Before Taxes 	5,702 	(1,153) 	(315) 	598 	16 	(854) 	6,556
Income Tax Provision (Benefit) 	891 	(241) (3) (34) (3) 132 (3) 5 (3) (139) 	1,030
Net Income from Continuing Operations 	4,811 	(912) 	(281) 	466 	11 	(715) 	5,526
Net Income from Continuing Operations Attributable
to Merck & Co., Inc. 4,812 	(912) 	(281) 	466 	11 	(715) 	5,527
Earnings per Common Share Assuming Dilution from
Continuing Operations 1.89	$ 	(0.36) 	(0.11) 	0.18 	0.01 	(0.28) 	2.17	$
Tax Rate 	15.6% 	15.7%
Only the line items that are affected by non-GAAP adjustments are shown.
Non-GAAP
Merck is providing certain non-GAAP information that excludes certain items because of the nature of these items and the impact they have on the analysis of underlying business performance and trends. Management
believes that providing this information enhances investors’ understanding of the company’s results as it permits investors to understand how management assesses performance. Management uses these measures
internally for planning and forecasting purposes and to measure the performance of the company along with other metrics. In addition, senior management’s annual compensation is derived in part using non-GAAP pretax
income. This information should be considered in addition to, but not as a substitute for or superior to, information prepared in accordance with GAAP.
(1) Amounts included in cost of sales primarily reflect expenses for the amortization of intangible assets. Amounts included in selling, general and administrative (SG&A) expenses reflect acquisition and divestiture-related
costs, including $95 million of transaction costs in the six month period related to the acquisition of Arqule, Inc. Amounts included in research and development expenses primarily reflect a reduction in expenses related to a
decrease in the estimated fair value measurement of liabilities for contingent consideration. Amounts included in other (income) expense, net, primarily reflect costs related to increases in the estimated fair value
measurement of liabilities for contingent consideration, partially offset by royalty income related to the termination of the Sanofi-Pasteur MSD joint venture.
(2) Amounts primarily include employee separation costs and accelerated depreciation associated with facilities to be closed or divested related to activities under the company's formal restructuring programs.
(3) Represent the estimated tax impacts on the reconciling items based on applying the statutory rate of the originating territory of the non-GAAP adjustments.
GAAP Acquisition and Divestiture-
Related Costs (1) 	Restructuring Costs (2)
(Income) Loss from
Investments in Equity
Securities
Certain Other Items 	Adjustment Subtotal
The table below reflects a reconciliation of GAAP to non-GAAP financial information on a continuing operations basis. As Organon results are reflected within discontinued operations, they are
excluded from the financial information provided below.
MERCK & CO., INC.
SECOND QUARTER AND SIX MONTHS ENDED JUNE 30, 2020 GAAP TO NON-GAAP RECONCILIATION - CONTINUING OPERATIONS
(AMOUNTS IN MILLIONS, EXCEPT PER SHARE FIGURES)
(UNAUDITED)
Table 2b
4

-- 5 of 10 --

1Q 	2Q 	June YTD 	1Q 	2Q 	June YTD 	3Q 	4Q 	Full Year 	Nom % 	Ex-Exch % 	Nom % 	Ex-Exch %
TOTAL SALES (1) $10,627 	$11,402 	$22,029 	$10,288 	$9,353 	$19,641 	$10,929 	$10,948 	$41,518 	22 	19 	12 	10
PHARMACEUTICAL 	9,238 	9,980 	19,218 	8,905 	8,178 	17,083 	9,714 	9,813 	36,610 	22 	18 	12 	9
Oncology
Keytruda 	3,899 	4,176 	8,076 	3,284 	3,388 	6,672 	3,715 	3,993 	14,380 	23 	20 	21 	18
Alliance Revenue – Lynparza (2) 228 	248 	475 	145 	178 	323 	196 	206 	725 	39 	34 	47 	42
Alliance Revenue – Lenvima (2) 130 	181 	310 	128 	151 	279 	142 	158 	580 	19 	15 	11 	8
Vaccines (3)
Gardasil / Gardasil 9 	917 	1,234 	2,151 	1,097 	656 	1,753 	1,187 	998 	3,938 	88 	78 	23 	17
ProQuad / M-M-R II / Varivax 	449 	516 	965 	435 	378 	813 	576 	488 	1,878 	36 	35 	19 	17
Pneumovax 23 	171 	152 	323 	256 	117 	373 	375 	339 	1,087 	30 	27 	-13 	-16
RotaTeq 	158 	208 	366 	222 	168 	391 	210 	196 	797 	23 	19 	-6 	-8
Vaqta 	34 	56 	90 	60 	28 	88 	51 	31 	170 	101 	96 	2 	-
Hospital Acute Care
Bridion 	340 	387 	727 	299 	224 	524 	320 	355 	1,198 	72 	67 	39 	35
Prevymis 	82 	93 	174 	60 	63 	123 	77 	80 	281 	47 	41 	42 	36
Noxafil 	67 	66 	133 	94 	73 	168 	79 	82 	329 	-10 	-14 	-21 	-24
Primaxin 	65 	60 	125 	51 	64 	115 	74 	62 	251 	-6 	-14 	8 	-
Cancidas 	57 	54 	111 	55 	43 	98 	50 	65 	213 	24 	17 	13 	8
Invanz 	57 	48 	104 	64 	43 	108 	51 	53 	211 	10 	3 	-3 	-5
Zerbaxa 	(8) 	(1) 	(9) 	37 	32 	69 	43 	19 	130 	-104 	-104 	-113 	-113
Immunology
Simponi 	214 	202 	416 	215 	191 	406 	209 	223 	838 	5 	-3 	2 	-6
Remicade 	85 	75 	160 	88 	73 	160 	82 	88 	330 	3 	-3 	- 	-6
Neuroscience
Belsomra 	79 	78 	157 	79 	84 	163 	81 	83 	327 	-7 	-6 	-4 	-5
Virology
Isentress / Isentress HD 	209 	192 	401 	245 	196 	441 	205 	211 	857 	-2 	-5 	-9 	-11
Cardiovascular
Alliance Revenue - Adempas/Verquvo (4) 74 	74 	149 	53 	79 	133 	83 	65 	281 	-7 	13 	12 	23
Adempas (5) 55 	74 	129 	56 	57 	113 	55 	53 	220 	29 	23 	15 	7
Diabetes (6)
Januvia 	809 	784 	1,593 	774 	854 	1,628 	821 	857 	3,306 	-8 	-11 	-2 	-5
Janumet 	486 	477 	962 	503 	490 	993 	506 	472 	1,971 	-3 	-8 	-3 	-7
Other Pharmaceutical (7) 581 	546 	1,130 	605 	548 	1,149 	526 	636 	2,312 	- 	-5 	-2 	-6
ANIMAL HEALTH 	1,418 	1,472 	2,890 	1,214 	1,101 	2,314 	1,220 	1,168 	4,703 	34 	27 	25 	21
Livestock 	819 	821 	1,640 	739 	648 	1,386 	758 	794 	2,939 	27 	20 	18 	15
Companion Animals 	599 	651 	1,250 	475 	453 	928 	462 	374 	1,764 	44 	38 	35 	31
Other Revenues (8) (29) 	(50) 	(79) 	169 	74 	244 	(5) 	(33) 	205 	-167 	-1 	-132 	-15
2021 	2020 	2Q 	June YTD
MERCK & CO., INC.
FRANCHISE / KEY PRODUCT SALES - CONTINUING OPERATIONS
(AMOUNTS IN MILLIONS)
(UNAUDITED)
Table 3
(6) Total Diabetes sales were $1,363 million and $1,330 million in the first and second quarter of 2021, respectively, and $1,353 million, $1,418 million, $1,405 million and $1,412 million in the
first, second, third and fourth quarters of 2020, respectively.
(7) Includes Pharmaceutical products not individually shown above.
(8) Other Revenues are comprised primarily of third-party manufacturing sales and miscellaneous corporate revenues, including revenue hedging activities.
Sum of quarterly amounts may not equal year-to-date amounts due to rounding.
(1) Only select products are shown.
(2) Alliance Revenue represents Merck’s share of profits, which are product sales net of cost of sales and commercialization costs.
(3) Total Vaccines sales were $1,809 million and $2,293 million in the first and second quarter of 2021, respectively, and $2,155 million, $1,418 million, $2,521 million and $2,163 million in the
first, second, third and fourth quarters of 2020, respectively.
(4) Alliance Revenue represents Merck's share of profits from sales in Bayer's marketing territories, which are product sales net of cost of sales and commercialization costs.
(5) Net product sales in Merck's marketing territories.
5

-- 6 of 10 --

2Q 2021 	2Q 2020 	% Change 	2Q 2021 	2Q 2020 	% Change 	2Q 2021 	2Q 2020 	% Change
TOTAL SALES (1) $11,402 	$9,353 	22 	$5,100 	$4,322 	18 	$6,301 	$5,031 	25
PHARMACEUTICAL 	9,980 	8,178 	22 	4,647 	3,958 	17 	5,333 	4,220 	26
Oncology
Keytruda 	4,176 	3,388 	23 	2,347 	2,043 	15 	1,829 	1,345 	36
Alliance Revenue - Lynparza (2) 248 	178 	39 	124 	105 	18 	124 	73 	70
Alliance Revenue - Lenvima (2) 181 	151 	19 	88 	98 	-11 	93 	53 	74
Vaccines (3)
Gardasil / Gardasil 9 	1,234 	656 	88 	454 	168 	170 	781 	488 	60
ProQuad / M-M-R II / Varivax 	516 	378 	36 	386 	263 	47 	130 	115 	13
Pneumovax 23 	152 	117 	30 	100 	21 	* 	52 	96 	-46
RotaTeq 	208 	168 	23 	111 	100 	11 	97 	68 	43
Vaqta 	56 	28 	101 	22 	17 	34 	34 	11 	199
Hospital Acute Care
Bridion 	387 	224 	72 	197 	107 	84 	190 	117 	62
Prevymis 	93 	63 	47 	37 	28 	29 	56 	35 	61
Noxafil 	66 	73 	-10 	14 	6 	135 	52 	67 	-23
Primaxin 	60 	64 	-6 	0 	1 	-90 	60 	63 	-5
Cancidas 	54 	43 	24 	1 	(2) 	-132 	53 	45 	18
Invanz 	48 	43 	10 	(4) 	* 	52 	43 	20
Zerbaxa 	(1) 	32 	-104 	(2) 	17 	-111 	1 	15 	-96
Immunology
Simponi 	202 	191 	5 	202 	191 	5
Remicade 	75 	73 	3 	75 	73 	3
Neuroscience
Belsomra 	78 	84 	-7 	14 	22 	-36 	63 	61 	4
Virology
Isentress / Isentress HD 	192 	196 	-2 	74 	76 	-3 	118 	120 	-2
Cardiovascular
Alliance Revenue - Adempas/Verquvo (4) 74 	79 	-7 	81 	73 	10 	(7) 	6 	*
Adempas (5) 74 	57 	29 	74 	57 	29
Diabetes (6)
Januvia 	784 	854 	-8 	284 	413 	-31 	500 	441 	13
Janumet 	477 	490 	-3 	74 	143 	-48 	403 	348 	16
Other Pharmaceutical (7) 546 	548 	245 	259 	-5 	301 	289 	4
ANIMAL HEALTH 	1,472 	1,101 	34 	459 	342 	34 	1,012 	759 	33
Livestock 	821 	648 	27 	161 	122 	32 	659 	526 	25
Companion Animals 	651 	453 	44 	298 	220 	36 	353 	233 	51
Other Revenues (8) (50) 	74 	-167 	(6) 	22 	-127 	(44) 	52 	-184
* 200% or greater
Sum of U.S. plus international may not equal global due to rounding.
(3) Total Vaccines sales were $2,293 million in the second quarter of 2021 and $1,418 million in the second quarter of 2020.
MERCK & CO., INC.
FRANCHISE / KEY PRODUCT SALES - CONTINUING OPERATIONS
SECOND QUARTER 2021
(AMOUNTS IN MILLIONS)
(UNAUDITED)
Table 3a
Global 	U.S. 	International
(1) Only select products are shown.
(2) Alliance Revenue represents Merck’s share of profits, which are product sales net of cost of sales and commercialization costs.
(4) Alliance Revenue represents Merck's share of profits from sales in Bayer's marketing territories, which are product sales net of cost of sales and commercialization costs.
(5) Net product sales in Merck's marketing territories.
(6) Total Diabetes sales were $1,330 million in the second quarter of 2021 and $1,418 million in the second quarter of 2020.
(7) Includes Pharmaceutical products not individually shown above.
(8) Other Revenues are comprised primarily of third-party manufacturing sales and miscellaneous corporate revenues, including revenue hedging activities.
6

-- 7 of 10 --

June YTD
2021
June YTD
2020 	% Change
June YTD
2021
June YTD
2020 	% Change
June YTD
2021
June YTD
2020 	% Change
TOTAL SALES (1) $22,029 	$19,641 	12 	$9,890 	$9,053 	9 	$12,139 	$10,588 	15
PHARMACEUTICAL 	19,218 	17,083 	12 	8,941 	8,266 	8 	10,277 	8,818 	17
Oncology
Keytruda 	8,076 	6,672 	21 	4,528 	3,949 	15 	3,548 	2,722 	30
Alliance Revenue - Lynparza (2) 475 	323 	47 	242 	190 	28 	233 	133 	75
Alliance Revenue - Lenvima (2) 310 	279 	11 	173 	188 	-8 	137 	91 	50
Vaccines (3)
Gardasil / Gardasil 9 	2,151 	1,753 	23 	766 	629 	22 	1,385 	1,124 	23
ProQuad / M-M-R II / Varivax 	965 	813 	19 	718 	596 	20 	246 	217 	13
Pneumovax 23 	323 	373 	-13 	173 	203 	-15 	150 	170 	-12
RotaTeq 	366 	391 	-6 	229 	241 	-5 	137 	150 	-8
Vaqta 	90 	88 	2 	47 	47 	1 	43 	41 	4
Hospital Acute Care
Bridion 	727 	524 	39 	364 	250 	46 	363 	274 	32
Prevymis 	174 	123 	42 	72 	55 	31 	103 	68 	51
Noxafil 	133 	168 	-21 	29 	14 	113 	104 	154 	-32
Primaxin 	125 	115 	8 	1 	-92 	125 	114 	9
Cancidas 	111 	98 	13 	3 	1 	* 	108 	98 	11
Invanz 	104 	108 	-3 	6 	-94 	104 	102 	2
Zerbaxa 	(9) 	69 	-113 	(4) 	37 	-110 	(5) 	32 	-116
Immunology
Simponi 	416 	406 	2 	416 	406 	2
Remicade 	160 	160 	160 	160
Neuroscience
Belsomra 	157 	163 	-4 	32 	49 	-34 	125 	114 	10
Virology
Isentress / Isentress HD 	401 	441 	-9 	145 	151 	-4 	256 	290 	-12
Cardiovascular
Alliance Revenue - Adempas/Verquvo (4) 149 	133 	12 	149 	122 	22 	11 	-99
Adempas (5) 129 	113 	15 	129 	113 	15
Diabetes (6)
Januvia 	1,593 	1,628 	-2 	632 	768 	-18 	961 	860 	12
Janumet 	962 	993 	-3 	158 	256 	-38 	805 	737 	9
Other Pharmaceutical (7) 1,130 	1,149 	-2 	485 	513 	-5 	644 	637 	1
ANIMAL HEALTH 	2,890 	2,314 	25 	896 	726 	23 	1,994 	1,588 	26
Livestock 	1,640 	1,386 	18 	318 	284 	12 	1,322 	1,102 	20
Companion Animals 	1,250 	928 	35 	578 	442 	31 	672 	486 	38
Other Revenues (8) (79) 	244 	-132 	53 	61 	-13 	(132) 	182 	-172
* 200% or greater
Sum of U.S. plus international may not equal global due to rounding.
(3) Total Vaccines sales were $4,102 million and $3,574 million on a global basis for June YTD 2021 and 2020, respectively.
MERCK & CO., INC.
FRANCHISE / KEY PRODUCT SALES - CONTINUING OPERATIONS
JUNE YEAR-TO-DATE 2021
(AMOUNTS IN MILLIONS)
(UNAUDITED)
Table 3b
Global 	U.S. 	International
(1) Only select products are shown.
(2) Alliance Revenue represents Merck’s share of profits, which are product sales net of cost of sales and commercialization costs.
(4) Alliance Revenue represents Merck's share of profits from sales in Bayer's marketing territories, which are product sales net of cost of sales and commercialization costs.
(5) Net product sales in Merck's marketing territories.
(6) Total Diabetes sales were $2,693 million and $2,772 million on a global basis for June YTD 2021 and 2020, respectively.
(7) Includes Pharmaceutical products not individually shown above.
(8) Other Revenues are comprised primarily of third-party manufacturing sales and miscellaneous corporate revenues, including revenue hedging activities.
7

-- 8 of 10 --

TOTAL PHARMACEUTICAL 	$9,238 	$9,980 	$19,218 	$8,905 	$8,178 	$17,083 	$9,714 	$9,813 	$36,610 	22 	12
United States 	4,294 	4,647 	8,941 	4,308 	3,958 	8,266 	4,842 	4,903 	18,010 	17 	8
% Pharmaceutical Sales 	46.5% 	46.6% 	46.5% 	48.4% 	48.4% 	48.4% 	49.8% 	50.0% 	49.2%
Europe (1) 2,276 	2,404 	4,680 	2,116 	1,855 	3,971 	2,171 	2,314 	8,455 	30 	18
% Pharmaceutical Sales 	24.6% 	24.1% 	24.4% 	23.8% 	22.7% 	23.2% 	22.3% 	23.6% 	23.1%
China 	688 	944 	1,632 	628 	600 	1,228 	764 	670 	2,661 	57 	33
% Pharmaceutical Sales 	7.4% 	9.5% 	8.5% 	7.1% 	7.3% 	7.2% 	7.9% 	6.8% 	7.3%
Japan 	607 	637 	1,244 	561 	601 	1,162 	648 	704 	2,514 	6 	7
% Pharmaceutical Sales 	6.6% 	6.4% 	6.5% 	6.3% 	7.3% 	6.8% 	6.7% 	7.2% 	6.9%
Asia Pacific (other than China and Japan) 	437 	442 	879 	411 	377 	789 	411 	414 	1,614 	17 	11
% Pharmaceutical Sales 	4.7% 	4.4% 	4.6% 	4.6% 	4.6% 	4.6% 	4.2% 	4.2% 	4.4%
Latin America 	353 	379 	732 	314 	312 	626 	372 	371 	1,369 	21 	17
% Pharmaceutical Sales 	3.8% 	3.8% 	3.8% 	3.5% 	3.8% 	3.7% 	3.8% 	3.8% 	3.7%
Eastern Europe/Middle East/Africa 	357 	318 	675 	353 	309 	659 	289 	251 	1,199 	3 	2
% Pharmaceutical Sales 	3.9% 	3.2% 	3.5% 	4.0% 	3.8% 	3.9% 	3.0% 	2.6% 	3.3%
Canada 	160 	157 	318 	159 	121 	280 	169 	149 	599 	31 	14
% Pharmaceutical Sales 	1.7% 	1.6% 	1.7% 	1.8% 	1.5% 	1.6% 	1.7% 	1.5% 	1.6%
Other 	66 	52 	117 	55 	45 	102 	48 	37 	189 	16 	15
% Pharmaceutical Sales 	0.8% 	0.4% 	0.5% 	0.5% 	0.6% 	0.6% 	0.6% 	0.3% 	0.5%
2021 	2020 	% Change
MERCK & CO., INC.
PHARMACEUTICAL GEOGRAPHIC SALES - CONTINUING OPERATIONS
(AMOUNTS IN MILLIONS)
(UNAUDITED)
Table 3c
June YTD
Sum of quarterly amounts may not equal year-to-date amounts due to rounding.
1Q 	2Q 	June YTD 	1Q 	2Q 	June YTD
(1) Europe represents all European Union countries, the European Union accession markets and the United Kingdom.
3Q 	4Q 	Full Year 	2Q
8

-- 9 of 10 --

OTHER (INCOME) EXPENSE, NET
2Q21 	2Q20
June YTD
2021
June YTD
2020
Interest income 	(9)	$ 	(14)	$ 	(20)	$ 	(39)	$
Interest expense 	202 	209 	401 	421
Exchange losses 	114 	24 	155 	78
Income from investments in equity securities, net (1) (280) 	(551) 	(854) 	(603)
Net periodic defined benefit plan (credit) cost other than service cost 	(110) 	(80) 	(199) 	(170)
Other, net 	(20) 	25 	(41) 	(12)
Total 	(103)	$ 	(387)	$ 	(558)	$ 	(325)	$
(1) Includes net realized and unrealized gains and losses from investments in equity securities either owned directly or through ownership interests in investment funds.
Unrealized gains and losses from investments that are directly owned are determined at the end of the reporting period, while ownership interests in investment funds
are accounted for on a one quarter lag.
MERCK & CO., INC.
OTHER (INCOME) EXPENSE, NET - GAAP
(AMOUNTS IN MILLIONS)
(UNAUDITED)
Table 4
9

-- 10 of 10 --